News

What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock. One that is trading at attractive levels is even more preferable. Excellent dividend payers

Burns Matteson Capital Management, LLC reported a new stake in UnitedHealth Group (NYSE:UNH), acquiring 8,017 shares in the third quarter of 2025, an estimated $2.77 million trade as of the end of

On October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV disclosed in an SEC filing that it sold out of Pfizer(NYSE:PFE), with an estimated $2.66 million trade.

According to a Securities and

On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (NYSE:PFE), adding shares worth an estimated $6.8 million in the third quarter.

QSM Asset Management increased its position in

Over the past decade, pharmaceutical maker Pfizer (NYSE: PFE) has severely lagged the market. Dividends reinvested aside, the stock is in the red over this period, while the S&P 500 is up by almost

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

An SEC filing dated

On October 10, 2025, Sarasin & Partners LLP disclosed a significant reduction in its UnitedHealth Group (NYSE:UNH) stake, selling 465,744 shares in an estimated $140.86 million trade.

Sarasin &amp

The 6.7% dividend yield on offer from Pfizer (NYSE: PFE) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable. But

UnitedHealth (NYSE: UNH) shares are up significantly since I upgraded the stock to a buy rating.

*Stock prices used were the afternoon prices of Oct. 6, 2025. The video was published on Oct. 8

There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer

Shares in Viking Therapeutics (NASDAQ: VKTX) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical

Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.

According to a filing

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices

Shares of America's largest health insurer, UnitedHealth Group, have been on a relatively wild ride. After hitting a peak in April, the stock fell by more than half.

Shares of UnitedHealth Group

Pfizer (NYSE: PFE) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news. But Pfizer's price rebound

According to an SEC filing dated October 2, 2025, St. Louis Financial Planners Asset Management, LLC initiated a new stake in UnitedHealth Group (NYSE:UNH), purchasing 12,542 shares during the third

Pfizer (NYSE: PFE) made a deal with the White House to avoid paying tariffs on imported products.

*Stock prices used were the afternoon prices of Oct. 3, 2025. The video was published on Oct. 5

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The

Pfizer (NYSE: PFE) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.

It has developed many medicines over the years

Health insurer UnitedHealth Group (NYSE: UNH) reports its third-quarter earnings results later this month, on Oct. 28. It could be a pivotal report for the company, which indicates whether the

Shares in Eli Lilly (NYSE: LLY) had risen 13.2% in the week to Friday morning. The move comes at a time when peer Pfizer announced a deal with the Trump administration that gave that pharmaceutical

The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald

Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early

The big draw for most investors with Pfizer (NYSE: PFE) today is likely to be its lofty 7.2% dividend yield. That compares to 1.2% for the S&P 500 index and about 1.3% for the average pharmaceutical